Research on new and better ways to treat cancer. Covers radiotherapy, targeted microdroplets, nerve-injury protection, drug combinations, and tumor models.
A new study by Dana-Farber Cancer Institute researchers found that CAR-T therapy offers superior event-free and overall survival compared to salvage chemoimmunotherapy. However, the current list price of $400,000 per infusion makes cost-effectiveness a concern.
A recent study by Goethe University Frankfurt has identified a mechanism that could be a suitable starting point for developing novel drugs against leukemia cells. The researchers discovered that the mutated NPM1 gene variant drives pro-autophagic activity, enabling cancer cells to recycle their structures and meet their needs.
Researchers from Japan have discovered a novel targeted molecular therapy using microRNA-451a to suppress the progression of gemcitabine-resistant biliary tract cancers. The study found that miR-451a significantly diminished cell proliferation, induced cell death, and reduced chemoresistance in cancer cells.
Researchers at the University of Virginia Health System have discovered how Lactobacillus, a bacterium found in fermented foods and yogurt, influences mood disorders. The findings suggest that maintaining a healthy level of Lactobacillus may help prevent depression and anxiety by regulating immune response to stress.
Researchers found that carboxylic nanodiamonds blocked melanoma cells' ability to migrate and invade across membranes. Mice treated with these nanoparticles showed reduced or no tumor metastasis compared to untreated mice.
Researchers at Gladstone Institutes used CRISPR to destroy glioblastoma cells in an approach that could be applied to other highly mutated cancers. The technique, dubbed "cancer shredding," targets and rapidly eliminates tumor cells while sparing healthy ones.
A new study by Tulane University has identified a previously unknown molecular pathway that could halt lung cancer growth. The research found that protein RBM10 can suppress lung cancer by targeting the function of c-Myc, a protein that drives cancer cell growth and proliferation.
Researchers uncover intricate interplay between enhancers and silencers influenced by DNA methylation, providing crucial insights into dynamic gene control. High-resolution mapping reveals how genes are controlled and modified, paving the way for precision medicine tailored to individual patients.
Researchers have developed a new method, SECRE, to identify genetic regulators of cytokine secretion in autoimmune diseases. The technique has been validated on cells known to play a crucial role in inflammatory bowel disease (IBD) and shows promising results for treating conditions with few therapeutic options.
Researchers from The University of Texas at Austin have demonstrated a compact particle accelerator that produces an electron beam with an energy of 10 billion electron volts (10 GeV) in a chamber less than 20 meters long. The breakthrough uses nanoparticles to boost the energy delivered to electrons, enabling new applications in semic...
Researchers found that 1,8-cineole inhibits inflammatory pathways in the gut, while ginsenoside Rk2 alleviates liver inflammation and restores intestinal barrier function. Another compound, specnuezhenide, modifies gut microbiota and has potential to inhibit colorectal tumor growth.
A new study found that most people with colorectal cancer in sub-Saharan Africa receive inadequate treatment, leading to significantly improved life expectancy through simple measures. The mortality rate is up to 3.5 times higher in regions studied compared to countries with medium HDI scores.
Researchers developed an AI model using epigenetic factors to predict patient outcomes across multiple cancer types. The model successfully divided patients into two groups with different survival chances, and its genes were found to have a significant overlap with cluster-defining signature genes.
A study published in PLOS ONE found that 35% of women with breast cancer used self-discovered or peer-recommended techniques to enhance their sexual function. These techniques fell into four main domains: pain reduction, intimacy and relationship enhancement, desire and arousal enhancement, and emotional coping.
A recent study by Harvard researchers provides an engineering approach to understanding the failure of macrophages in cancer therapies. The team found that different phenotypes exhibit different penetration into tumors, with M0 macrophages showing improved transport efficiency.
A novel droplet digital PCR assay detects KMT2A fusion markers in AML patients, enabling sensitive MRD detection and guiding treatment decisions. This breakthrough may improve patient outcomes by assessing response to therapy and long-term surveillance.
A team of researchers developed a gel delivery system that overcomes challenges in intratumoral therapy. The gel contains an imaging agent and can hold a high concentration of drug for slow release. In preclinical models, the treatment induced tumor regression and improved survival in immunotherapy-resistant colon and breast cancer.
A study of 3.5 million patients diagnosed with cancer found a deficit in cancer treatments during the first year of the pandemic. The data showed decreases in cancer diagnoses but not changes in treatment strategies, highlighting the impact of the pandemic on cancer care.
Researchers at IRB Barcelona have identified the mechanism by which the MAF protein promotes breast cancer metastasis, revealing a key interaction with the estrogen receptor. This finding opens up new therapeutic options for patients with high MAF levels, who may benefit from treatments aimed at preventing metastases.
A Mayo Clinic study found patients with lower extremity lymphedema had twice the risk of developing skin cancer, including basal cell carcinomas and squamous cell carcinomas. Regular skin cancer screenings are crucial for these patients as early detection is critical.
A new study published in BMJ Mental Health reveals that people with severe mental health issues are almost twice as likely to experience multimorbidity, a combination of chronic diseases. The research emphasizes the urgent need for a comprehensive and integrated approach to address this critical issue.
Scientists at Nagoya University have discovered a reliable cancer marker, stromal cell-derived factor 4 (SDF-4), that detects gastric cancer with high accuracy. The protein is found in high levels even in patients with stage I gastric cancer, suggesting its potential for early detection.
Researchers found that breast cancer cells rely on vitamin B5 to grow and survive. In a study published in Nature Metabolism, scientists discovered that limiting vitamin B5 intake slowed the growth of breast cancer tumours in mice.
Researchers developed a technique to capture extracellular vesicles using sustainable wood cellulose-based nanofiber sheets, revealing new insights into cancer treatment. The technology has the potential to revolutionize early cancer diagnosis and open up personalized medicine.
Researchers at the University of Leicester have received a significant financial boost to advance their cancer treatment research. The team will investigate 'liquid biopsies' to reveal vital clues about cancer genetic makeup, aiming to predict how cancer changes and which treatment works best for individual patients.
Researchers found that a high-sugar diet causes insulin resistance in the brain, reducing its ability to remove neuronal debris and increasing the risk of neurodegenerative diseases. This study provides insight into how obesity-inducing diets contribute to disease risk.
A study published in Oncotarget reveals that HER2 mutant alleles play a crucial role in determining treatment response to neratinib and poziotinib. Researchers found that individual HER2 mutant alleles have distinct effects on therapeutic efficacy, suggesting new targets for breast cancer therapy.
Researchers describe the use of ripretinib and repeated surgical resection in a patient with recurrent GIST harboring a KIT exon 11 mutation. The treatment led to extended clinical benefit, outperforming current reported data from ripretinib clinical trials.
A new smartphone app using the APRI+ALBI score increases the safety of liver surgery by providing an individualized risk assessment for patients prior to resection. The score offers a cheaper and less invasive option with comparable predictive power compared to standard preoperative tests.
Researchers have discovered a novel biomarker that enables the evaluation of near-infrared photoimmunotherapy (NIR-PIT) treatment success. The biomarker uses microbubbles to track tumor vessels and measure the effectiveness of NIR-PIT, which combines antibodies and near-infrared light to destroy cancer cells.
Researchers developed a new tool to evaluate clinical trial results, allowing for more complex research questions and faster treatment access. The 'Chauhan Weighted Trajectory Analysis' can assess multiple outcomes in one graph, capturing disease severity and treatment effectiveness.
A study by Medical University of Vienna found that AI algorithms in smartphone applications perform well in diagnosing pigmented skin lesions, but are outperformed by doctors in treatment decisions. The 7-class algorithm showed equivalent diagnostic accuracy to experts, while the ISIC algorithm performed worse.
Researchers develop a novel iNKT cell therapy approach using canine models, demonstrating improved survival and longer therapeutic effect. The platform could potentially treat human cancers with reduced risk of relapse and increased efficacy.
A study of 5,435 adolescents and young adults with cancer found that those receiving specialty palliative care experienced a decrease in pain severity. However, the intervention did not affect other symptoms, highlighting the need for new interventions targeting other symptoms during treatment.
A new AI-based tool estimates patient-specific cancer survival rates using machine learning, offering personalized prognosis for patients with breast, thyroid, and pancreatic cancers. The Cancer Survival Calculator differs from existing estimators by incorporating multiple factors beyond disease stage.
Researchers from Columbia University have validated GLS2's ability to promote ferroptosis in murine models. This study suggests that targeting GLS2 may be a potential therapeutic strategy against liver diseases, particularly hepatocellular carcinoma.
A study by researchers at Keck School of Medicine of USC found that Black cancer survivors experience slowdowns in diagnosis and delivery of care due to exposure to racial discrimination. Positive interactions, such as ready access to providers and displays of empathy, were identified as key factors in improving care.
Researchers at Osaka University have developed a novel radioactive antibody that can diagnose and treat a deadly type of pancreatic cancer. The antibody targets glypican-1, a protein highly expressed in PDAC tumors, allowing for early detection and treatment with improved survival rates.
A new blood test called OvaPrint TM detects specific nucleic acids in the blood, distinguishing between cancerous and benign pelvic masses with high accuracy. The test has the potential to improve treatment outcomes by identifying the best surgical approach for patients with a pelvic mass.
Researchers discovered elevated miR-18a-5p expression in PCa patients with bone metastases, which inhibited osteoblast differentiation and activity. Inhibiting miR-18a-5p improved bone biomechanical properties and bone mineral mass in a mouse model.
Researchers identified the integration site pattern of lentiviral gene therapies in patient cells, shedding light on treatment safety and efficacy. The study found that integration near nuclear pores is associated with improved safety and effectiveness, avoiding oncogene regions where earlier technologies failed.
The study analyzed 10,000 gene expression signatures to assess their prognostic ability, finding that they lead to accurate patient prognosis in no more than 80% of cases. The researchers emphasize the need for a comprehensive approach incorporating molecular, clinical, histological, and other factors to ensure an accurate prognosis.
Researchers identified a 'guard mechanism' controlling protein GPB1 to attack microbes and cancer cells. The study found that disrupting this mechanism can kill pathogens like Toxoplasma and potentially treat cancer.
Researchers classify UGDH as a molecular indicator of tumor progression in multiple cancer types, describing its involvement in key canonical cancer signaling pathways. Methods to inhibit UGDH and its downstream products are also identified.
Researchers identified a circulating tumor DNA (ctDNA) biomarker that can predict disease recurrence and response to treatment in patients with BRAF-negative melanoma. The study found that measuring ctDNA levels and variants can help tailor therapy and improve patient outcomes.
A team of researchers at Mays Cancer Center has identified protein markers that could signal the early development of metastatic lung cancer. These markers have led to a $1.6 million grant and will pave the way for a clinical trial in patients with advanced lung cancer.
Researchers developed three new two-photon probes that can visualize organelles in cells, enabling better understanding of cellular functions and tissue imaging. The probes are designed to detect pH levels, viscosity, and ionic species, providing more specific insights into cell viability and treatment responses.
Researchers at Northwestern University identified a new evolutionarily conserved RNAi-based form of cell death called Death Induced by Survival gene Elimination (DISE), which targets essential survival genes in cancer cells. This mechanism is ancient and effective against all cancers tested.
Scientists from Tokyo Metropolitan University have created a new polymer that can effectively transport plasmid DNA into T-cells during CAR T-cell therapy. The polymer, called PAMAM-G2-Gu, is stable, non-toxic, and doesn't use viruses, making it a promising candidate for next-gen gene carriers.
The article discusses the need to reassess COVID-19 precautions in 2023, particularly for patients with hematologic malignancies. The researchers highlight the increased risk of poor response to vaccination and worse outcomes from COVID-19 infection among these patients.
The American Society for Radiation Oncology announced the winners of its new combination therapy challenge, which aims to improve prostate cancer treatments using relugolix in combination with radiation therapy. The three winning research proposals will receive funding over four to five years.
The University of Texas at Arlington research team aims to develop a novel statistical model and machine learning algorithm to predict which patients will be cured from diseases such as cancer or cardiovascular disease. The goal is to identify patients who require additional treatments, thereby improving precision medicine.
Researchers have identified 11 genes associated with aggressive prostate cancer, which could lead to more effective treatments and earlier detection. The findings come from a large-scale study of over 17,500 patients and may help personalize care for individuals with the disease.
The September issue of the CHEST journal features research on long COVID, including a review on exercise pathophysiology in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Postacute Sequelae of SARS-CoV-2. Original studies also explore asthma treatment with albuterol-budesonide inhalers and sleep therapy using oronasal masks.
Researchers at the University of Nottingham have developed a new way to target and kill glioblastoma cells, a type of brain cancer with a low five-year survival rate. The breakthrough uses bio-nanoantennae to induce programmed cell death in cancer cells via electrical stimulation.
Researchers have discovered two FDA-approved and EMA-approved drugs that inhibit prmt5, a protein linked to promoting tumor growth in several cancers. These repurposed drugs show promise in reducing cancer cell proliferation and tumor growth.
Researchers at NYU Abu Dhabi have developed acidity-triggered rational membrane peptide-functionalized nanospheres that combine tumor detection and monitoring with potent, light-triggered cancer therapy. These nanospheres enable improved efficacy of phototherapies with minimal systemic toxicity.
Preclinical data shows GP-2250's antineoplastic activity in pancreatic tumor cell lines, reducing ATP levels and inhibiting NF-kB. The compound targets aerobic glycolysis, a hallmark of cancer metabolism, providing a potential treatment for various cancers.
Researchers discovered NSMF protein's role in alleviating DNA replication stress by displacing weakly bound RPA proteins and promoting phosphorylation. This mechanism accelerates relief of replication stress, offering a new direction for treating various diseases, including cancer and age-related conditions.
Researchers at UTSA are studying the bioactive properties of Sweet Annie, a plant used in traditional Chinese medicine for over 2,000 years. The study reveals that arteannuin B from the plant has anti-COVID and anti-glioblastoma properties, offering new avenues for targeted therapy.